| Title | Cost-effectiveness of varenicline for smoking cessation. | | Author(s) | Keiding H | | Institution | Department of Economics, University of Copenhagen, Studiestraede 6, DK-1455 Copenhagen K, Denmark. hans.keiding@pop.oko.ku.dk. | | Source | Expert Rev Pharmacoecon Outcomes Res 2009 Jun; 9(3):215-21. | | Abstract | Smoking cessation therapies are among the most cost-effective preventive healthcare measures. Varenicline is a relatively new drug developed especially for this purpose, and it has been shown to achieve better quit rates than nicotine replacement therapies and the non-nicotine-based drug, bupropion, which has been in use for some years. The cost-effectiveness of varenicline depends on the cost of the therapy and the cost-savings achieved through reduced morbidity and mortality; several investigations, based on the situation in different countries, indicate that varenicline either finances itself fully through the cost-savings achieved or offers additional life-years at a lower price than that paid elsewhere in the healthcare sector. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19527093 |
|
